Drug intelligence / Profile preview

H7N1 influenza vaccine

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intratracheal, Conjunctival, In Ovo

Overview

The H7N1 influenza vaccine is a vaccine developed by GlaxoSmithKline (GSK) Biologicals for the prevention of influenza. It is designed to stimulate the immune system to produce antibodies that recognize and neutralize the H7N1 influenza virus. Specifically, it induces antibodies against the hemagglutinin (HA) and neuraminidase (NA) proteins of the virus. Clinical trials have evaluated the safety and immunogenicity of different formulations of this vaccine in adults. [cite: NCT01949090, NCT01934127, 3, 5, 11, 13]

Targets

N1 NA (Influenza A neuraminidase N1)HA (Hemagglutinin)

Beyond the preview

Go deeper on H7N1 influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H7N1 influenza vaccine.

Explore the full profile